Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy

BACKGROUND: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC. METHODS: National registry d...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrankar, Martina, Kern, Izidor, Stanic, Karmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594267/
https://www.ncbi.nlm.nih.gov/pubmed/33121520
http://dx.doi.org/10.1186/s13014-020-01696-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594267/
https://www.ncbi.nlm.nih.gov/pubmed/33121520
http://dx.doi.org/10.1186/s13014-020-01696-z

Ejemplares similares